EX-99.12abt-2025q2xexhibitx991.htmEX-99.1 Document
Exhibit 99.1
News Release
Abbott Reports Second-Quarter 2025 Results
–Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1
–Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26
–Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase
–Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase
ABBOTT PARK, Ill., July 17, 2025 — Abbott today announced financial results for the second quarter ended June 30, 2025.
•Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.
•Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year.
•First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales2.
•Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
•Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint.
•In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex™ Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).
•In April, Abbott announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) clinical feasibility study. This study was the world's first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart's natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms.
•In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease.
•Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026."
Page 1 of 20
SECOND-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
U.S.
4,276
957
811
—
2,503
International
6,866
1,255
1,362
1,383
2,866
Total reported
11,142
2,212
2,173
1,383
5,369
% Change vs. 2Q24
U.S.
8.7
2.6
(0.1)
n/a
14.6
International
6.6
3.1
(1.5)
6.9
12.4
Total reported
7.4
2.9
(1.0)
6.9
13.4
Impact of foreign exchange
0.5
(0.5)
0.4
(0.8)
1.2
Organic
6.9
3.4
(1.4)
7.7
12.2
Impact of COVID-19 testing sales 1
(0.6)
—
(2.2)
—
—
Organic (excluding COVID-19 tests)
7.5
3.4
0.8
7.7
12.2
Organic
U.S.
8.7
2.6
(0.1)
n/a
14.6
International
5.8
4.0
(2.2)
7.7
10.1
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total Company
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
U.S.
8,444
1,912
1,682
—
4,842
International
13,056
2,446
2,545
2,643
5,422
Total reported
21,500
4,358
4,227
2,643
10,264
% Change vs. 1H24
U.S.
8.5
5.6
(3.5)
n/a
14.8
International
3.9
1.6
(4.5)
4.9
9.1
Total reported
5.7
3.3
(4.1)
4.9
11.7
Impact of foreign exchange
(1.1)
(1.5)
(0.9)
(2.9)
(0.7)
Impact of business exit*
(0.1)
(0.3)
—
—
—
Organic
6.9
5.1
(3.2)
7.8
12.4
Impact of COVID-19 testing sales 2
(1.0)
—
(3.9)
—
—
Organic (excluding COVID-19 tests)
7.9
5.1
0.7
7.8
12.4
Organic
U.S.
8.7
6.4
(3.5)
n/a
14.8
International
5.8
4.1
(3.0)
7.8
10.3
Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.
Page 2 of 20
Nutrition
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Pediatric
Adult
U.S.
957
587
370
International
1,255
467
788
Total reported
2,212
1,054
1,158
% Change vs. 2Q24
U.S.
2.6
4.2
0.2
International
3.1
(5.7)
9.2
Total reported
2.9
(0.4)
6.1
Impact of foreign exchange
(0.5)
(0.6)
(0.5)
Organic
3.4
0.2
6.6
U.S.
2.6
4.2
0.2
International
4.0
(4.5)
9.8
Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter.
Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Pediatric
Adult
U.S.
1,912
1,175
737
International
2,446
920
1,526
Total reported
4,358
2,095
2,263
% Change vs. 1H24
U.S.
5.6
9.0
0.6
International
1.6
(7.0)
7.7
Total reported
3.3
1.3
5.3
Impact of foreign exchange
(1.5)
(1.2)
(1.6)
Impact of business exit*
(0.3)
—
(0.7)
Organic
5.1
2.5
7.6
U.S.
6.4
9.0
2.4
International
4.1
(4.6)
10.2
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.
Page 3 of 20
Diagnostics
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid Diagnostics
U.S.
811
351
35
104
321
International
1,362
1,007
88
44
223
Total reported
2,173
1,358
123
148
544
% Change vs. 2Q24
U.S.
(0.1)
7.3
5.5
(2.0)
(7.1)
International
(1.5)
0.5
(5.6)
(11.9)
(6.1)
Total reported
(1.0)
2.2
(2.7)
(5.1)
(6.7)
Impact of foreign exchange
0.4
0.6
0.7
0.1
0.1
Organic
(1.4)
1.6
(3.4)
(5.2)
(6.8)
U.S.
(0.1)
7.3
5.5
(2.0)
(7.1)
International
(2.2)
(0.3)
(6.5)
(12.1)
(6.3)
Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales1.
Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China.
COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year.
Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Core Laboratory
Molecular
Point of Care
Rapid Diagnostics
U.S.
1,682
683
75
204
720
International
2,545
1,852
170
86
437
Total reported
4,227
2,535
245
290
1,157
% Change vs. 1H24
U.S.
(3.5)
7.2
—
(0.3)
(12.8)
International
(4.5)
(2.4)
(6.1)
(4.5)
(12.3)
Total reported
(4.1)
0.1
(4.4)
(1.6)
(12.6)
Impact of foreign exchange
(0.9)
(1.2)
(1.0)
(0.4)
(0.6)
Organic
(3.2)
1.3
(3.4)
(1.2)
(12.0)
U.S.
(3.5)
7.2
—
(0.3)
(12.8)
International
(3.0)
(0.7)
(4.9)
(3.3)
(10.7)
Page 4 of 20
Established Pharmaceuticals
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Key Emerging Markets
Other
U.S.
—
—
—
International
1,383
1,059
324
Total reported
1,383
1,059
324
% Change vs. 2Q24
U.S.
n/a
n/a
n/a
International
6.9
7.3
5.9
Total reported
6.9
7.3
5.9
Impact of foreign exchange
(0.8)
(1.4)
1.4
Organic
7.7
8.7
4.5
U.S.
n/a
n/a
n/a
International
7.7
8.7
4.5
Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Key Emerging Markets
Other
U.S.
—
—
—
International
2,643
2,024
619
Total reported
2,643
2,024
619
% Change vs. 1H24
U.S.
n/a
n/a
n/a
International
4.9
5.7
2.4
Total reported
4.9
5.7
2.4
Impact of foreign exchange
(2.9)
(3.3)
(1.4)
Organic
7.8
9.0
3.8
U.S.
n/a
n/a
n/a
International
7.8
9.0
3.8
Page 5 of 20
Medical Devices
Second Quarter 2025 Results (2Q25)
Sales 2Q25 ($ in millions)
Total
Rhythm Management
Electro-
physiology
Heart Failure
Vascular
Structural Heart
Neuro-modulation
Diabetes Care
U.S.
2,503
340
322
282
283
289
193
794
International
2,866
333
378
86
474
347
61
1,187
Total reported
5,369
673
700
368
757
636
254
1,981
% Change vs. 2Q24
U.S.
14.6
16.5
12.2
15.8
3.0
12.2
0.4
24.5
International
12.4
5.7
10.9
11.2
5.4
13.7
20.4
17.5
Total reported
13.4
10.9
11.5
14.7
4.5
13.0
4.6
20.2
Impact of foreign exchange
1.2
1.1
1.2
0.7
1.0
1.3
0.3
1.7
Organic
12.2
9.8
10.3
14.0
3.5
11.7
4.3
18.5
U.S.
14.6
16.5
12.2
15.8
3.0
12.2
0.4
24.5
International
10.1
3.6
8.8
8.4
3.8
11.4
18.7
14.7
Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter.
Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology.
Several products contributed to the strong performance, including FreeStyle Libre®, Navitor®, TriClip® and AVEIR®.
In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis.
First Half 2025 Results (1H25)
Sales 1H25 ($ in millions)
Total
Rhythm Management
Electro-
physiology
Heart Failure
Vascular
Structural Heart
Neuro-modulation
Diabetes Care
U.S.
4,842
644
621
544
551
571
369
1,542
International
5,422
614
708
163
916
642
113
2,266
Total reported
10,264
1,258
1,329
707
1,467
1,213
482
3,808
% Change vs. 1H24
U.S.
14.8
14.4
11.7
13.2
4.2
16.3
(1.1)
25.7
International
9.1
1.2
7.6
12.6
3.5
9.3
18.5
13.8
Total reported
11.7
7.6
9.5
13.1
3.8
12.5
2.9
18.4
Impact of foreign exchange
(0.7)
(0.4)
(0.6)
(0.2)
(0.7)
(0.7)
(0.4)
(0.7)
Organic
12.4
8.0
10.1
13.3
4.5
13.2
3.3
19.1
U.S.
14.8
14.4
11.7
13.2
4.2
16.3
(1.1)
25.7
International
10.3
2.0
8.8
13.4
4.8
10.5
20.5
15.0
Page 6 of 20
ABBOTT'S FINANCIAL GUIDANCE
G1G2Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
G3Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales.
G4G5Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
ABBOTT DECLARES 406th CONSECUTIVE QUARTERLY DIVIDEND
On June 13, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025.
Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
Page 7 of 20
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika McLoughlin, 224-399-5082
Randy Blakley, 224-361-7966
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965
1.In the second quarter of 2025, total worldwide sales were $11.142 billion, total Diagnostics sales were $2.173 billion and COVID-19 testing-related sales were $55 million. In the second quarter of 2024, total worldwide sales were $10.377 billion, total Diagnostics sales were $2.195 billion and COVID-19 testing-related sales were $102 million.
2.In the first half of 2025, total worldwide sales were $21.500 billion, total Diagnostics sales were $4.227 billion and COVID-19 testing-related sales were $139 million. In the first half of 2024, total worldwide sales were $20.341 billion, total Diagnostics sales were $4.409 billion and COVID-19 testing-related sales were $306 million.
Page 8 of 20
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Second Quarter Ended June 30, 2025 and 2024
(in millions, except per share data)
(unaudited)
2Q25
2Q24
% Change
Net Sales
$11,142
$10,377
7.4
Cost of products sold, excluding amortization expense
4,854
4,603
5.5
Amortization of intangible assets
420
471
(10.7)
Research and development
725
698
3.9
Selling, general, and administrative
3,091
2,936
5.3
Total Operating Cost and Expenses
9,090
8,708
4.4
Operating Earnings
2,052
1,669
23.0
Interest expense, net
50
58
(14.2)
Net foreign exchange (gain) loss
(11)
(6)
55.6
Other (income) expense, net
(137)
10
n/m
Earnings before taxes
2,150
1,607
33.8
Taxes on earnings
371
305
21.3
1)
Net Earnings
$1,779
$1,302
36.7
Net Earnings excluding Specified Items, as described below
$2,213
$2,003
10.5
2)
Diluted Earnings per Common Share
$1.01
$0.74
36.5
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$1.26
$1.14
10.5
2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,751
1,751
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 9 of 20
1)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2)2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.
Page 10 of 20
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Half Ended June 30, 2025 and 2024
(in millions, except per share data)
(unaudited)
1H25
1H24
% Change
Net Sales
$21,500
$20,341
5.7
Cost of products sold, excluding amortization expense
9,322
9,066
2.8
Amortization of intangible assets
840
943
(10.8)
Research and development
1,441
1,382
4.3
Selling, general, and administrative
6,152
5,895
4.4
Total Operating Cost and Expenses
17,755
17,286
2.7
Operating Earnings
3,745
3,055
22.6
Interest expense, net
99
119
(16.4)
Net foreign exchange (gain) loss
(18)
(6)
n/m
Other (income) expense, net
(264)
(101)
n/m
Earnings before taxes
3,928
3,043
29.1
Taxes on earnings
824
516
59.5
1)
Net Earnings
$3,104
$2,527
22.9
Net Earnings excluding Specified Items, as described below
$4,132
$3,732
10.7
2)
Diluted Earnings per Common Share
$1.77
$1.44
22.9
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$2.35
$2.12
10.8
2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,749
1,750
NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 11 of 20
1)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2)2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.
Page 12 of 20
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2025 and 2024
(in millions, except per share data)
(unaudited)
2Q25
As
Reported (GAAP)
Specified Items
As
Adjusted
Intangible Amortization
$
420
$
(420)
$
—
Gross Margin
5,868
478
6,346
R&D
725
(20)
705
SG&A
3,091
(1)
3,090
Other (income) expense, net
(137)
(1)
(138)
Earnings before taxes
2,150
500
2,650
Taxes on Earnings
371
66
437
Net Earnings
1,779
434
2,213
Diluted Earnings per Share
$
1.01
$
0.25
$
1.26
Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 17 for additional details regarding specified items.
2Q24
As
Reported (GAAP)
Specified Items
As
Adjusted
Intangible Amortization
$
471
$
(471)
$
—
Gross Margin
5,303
506
5,809
R&D
698
(41)
657
SG&A
2,936
(57)
2,879
Other (income) expense, net
10
(145)
(135)
Earnings before taxes
1,607
749
2,356
Taxes on Earnings
305
48
353
Net Earnings
1,302
701
2,003
Diluted Earnings per Share
$
0.74
$
0.40
$
1.14
Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 18 for additional details regarding specified items.
Page 13 of 20
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2025 and 2024
(in millions, except per share data)
(unaudited)
1H25
As
Reported (GAAP)
Specified Items
As
Adjusted
Intangible Amortization
$
840
$
(840)
$
—
Gross Margin
11,338
926
12,264
R&D
1,441
(47)
1,394
SG&A
6,152
(11)
6,141
Other (income) expense, net
(264)
(36)
(300)
Earnings before taxes
3,928
1,020
4,948
Taxes on Earnings
824
(8)
816
Net Earnings
3,104
1,028
4,132
Diluted Earnings per Share
$
1.77
$
0.58
$
2.35
Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 19 for additional details regarding specified items.
1H24
As
Reported (GAAP)
Specified Items
As
Adjusted
Intangible Amortization
$
943
$
(943)
$
—
Gross Margin
10,332
1,024
11,356
R&D
1,382
(62)
1,320
SG&A
5,895
(91)
5,804
Other (income) expense, net
(101)
(171)
(272)
Earnings before taxes
3,043
1,348
4,391
Taxes on Earnings
516
143
659
Net Earnings
2,527
1,205
3,732
Diluted Earnings per Share
$
1.44
$
0.68
$
2.12
Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 20 for additional details regarding specified items.
Page 14 of 20
A reconciliation of the second-quarter tax rates for 2025 and 2024 is shown below:
2Q25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
2,150
$
371
17.3
%
1)
Specified items
500
66
Excluding specified items
$
2,650
$
437
16.5
%
2Q24
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
1,607
$
305
19.0
%
2)
Specified items
749
48
Excluding specified items
$
2,356
$
353
15.0
%
1)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.
A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below:
1H25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
3,928
$
824
21.0
%
3)
Specified items
1,020
(8)
Excluding specified items
$
4,948
$
816
16.5
%
1H24
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
3,043
$
516
17.0
%
4)
Specified items
1,348
143
Excluding specified items
$
4,391
$
659
15.0
%
3)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.
Page 15 of 20
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
First Half Ended June 30, 2025 and 2024
($ in millions)
(unaudited)
1H25
1H24
% Change vs. 1H24
Non-GAAP
Abbott Reported
Abbott Reported
Impact from business exit (a)
Adjusted Revenue
Reported
Adjusted
Organic
Total Company
21,500
20,341
(13)
20,328
5.7
5.8
6.9
U.S.
8,444
7,780
(13)
7,767
8.5
8.7
8.7
Intl
13,056
12,561
—
12,561
3.9
3.9
5.8
Total Nutrition
4,358
4,218
(13)
4,205
3.3
3.6
5.1
U.S.
1,912
1,811
(13)
1,798
5.6
6.4
6.4
Intl
2,446
2,407
—
2,407
1.6
1.6
4.1
Adult Nutrition
2,263
2,150
(13)
2,137
5.3
6.0
7.6
U.S.
737
733
(13)
720
0.6
2.4
2.4
Intl
1,526
1,417
—
1,417
7.7
7.7
10.2
(a) Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.
Page 16 of 20
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$
1
$
55
$
420
$
2
$
478
R&D
—
(7)
—
(13)
(20)
SG&A
(3)
1
—
1
(1)
Other (income) expense, net
(1)
—
—
—
(1)
Earnings before taxes
$
5
$
61
$
420
$
14
500
Taxes on Earnings (d)
66
Net Earnings
$
434
Diluted Earnings per Share
$
0.25
The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 17 of 20
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2024
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$
1
$
32
$
471
$
2
$
506
R&D
(1)
1
—
(41)
(41)
SG&A
(11)
(10)
—
(36)
(57)
Other (income) expense, net
(147)
—
—
2
(145)
Earnings before taxes
$
160
$
41
$
471
$
77
749
Taxes on Earnings (d)
48
Net Earnings
$
701
Diluted Earnings per Share
$
0.40
The table above provides additional details regarding the specified items described on page 13.
a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR requirements for previously approved products and an intangible asset impairment charge.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
Page 18 of 20
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$
1
$
81
$
840
$
4
$
926
R&D
(1)
(23)
—
(23)
(47)
SG&A
(6)
(6)
—
1
(11)
Other (income) expense, net
(25)
—
—
(11)
(36)
Earnings before taxes
$
33
$
110
$
840
$
37
1,020
Taxes on Earnings (d)
(8)
Net Earnings
$
1,028
Diluted Earnings per Share
$
0.58
The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 19 of 20
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2024
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$
2
$
74
$
943
$
5
$
1,024
R&D
(4)
(1)
—
(57)
(62)
SG&A
(25)
(19)
—
(47)
(91)
Other (income) expense, net
(135)
—
—
(36)
(171)
Earnings before taxes
$
166
$
94
$
943
$
145
1,348
Taxes on Earnings (d)
143
Net Earnings
$
1,205
Diluted Earnings per Share
$
0.68
The table above provides additional details regarding the specified items described on page 14.
a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
Page 20 of 20
Mentions · how they’re counted
| Category | Underlined | Word counter | Model’s count |
|---|---|---|---|
| AI AI, artificial intelligence, generative AI, machine learning, large language model, LLM | 0 | — | — |
| Layoffs layoffs, RIF, headcount reduction, workforce optimization, restructuring | 21 | — | — |
| Recession recession, downturn, contraction, slowdown | 0 | — | — |
| Tariffs tariff, trade war, trade barriers, trade restrictions, trade policy | 0 | — | — |
| Buybacks share repurchase, buyback program | 0 | — | — |
Underlines use the same word lists the scores use. AI, recession and tariffs follow Palanor’s word counter, so those counts match it exactly on the same text. Layoffs and buybacks use the terms the model was given. The model’s count is an estimate by meaning, not by string, so it can differ from the underlines.
Source: SEC EDGAR · public domain · Highlights by Palanor